Andrew Baum
Stock Analyst at Citigroup
(2.88)
# 1,553
Out of 5,124 analysts
65
Total ratings
76.74%
Success rate
14.66%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $48 → $45 | $53.06 | -15.19% | 13 | Nov 17, 2025 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $25.17 | +3.30% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $107.44 | +7.04% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $39.65 | +0.88% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $220.18 | -2.35% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $1,041.51 | -14.07% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $4.90 | +104.08% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $49.02 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Nov 17, 2025
Maintains: Neutral
Price Target: $48 → $45
Current: $53.06
Upside: -15.19%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $25.17
Upside: +3.30%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $107.44
Upside: +7.04%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $39.65
Upside: +0.88%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $220.18
Upside: -2.35%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $1,041.51
Upside: -14.07%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $4.90
Upside: +104.08%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $49.02
Upside: -